Format

Send to

Choose Destination
Clin Pharmacokinet. 2016 Feb;55(2):249-55. doi: 10.1007/s40262-015-0315-x.

Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.

Author information

1
Department of Medical Oncology, Erasmus MC Cancer Institute, 's Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. l.binkhorst@erasmusmc.nl.
2
Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands. l.binkhorst@erasmusmc.nl.
3
Department of Psychiatry, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
4
Department of Medical Oncology, Erasmus MC Cancer Institute, 's Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands.
5
Department of Internal Medicine, Vlietland Hospital, Schiedam, The Netherlands.
6
Department of Internal Medicine, Franciscus Hospital, Roosendaal, The Netherlands.
7
Department of Internal Medicine, Elisabeth TweeSteden Hospital, Tilburg, The Netherlands.
8
Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
9
Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Abstract

BACKGROUND AND OBJECTIVE:

The anti-oestrogen tamoxifen requires metabolic activation to endoxifen by cytochrome P450 (CYP) enzymes, predominantly CYP2D6. Potent CYP2D6-inhibiting antidepressants can seriously disrupt tamoxifen metabolism, probably influencing the efficacy of tamoxifen. For this reason, paroxetine and fluoxetine are recommended not to be used with tamoxifen in breast cancer patients. We investigated the effects of switching potent CYP2D6-inhibiting antidepressants to weak CYP2D6-inhibiting antidepressants on the plasma pharmacokinetics of tamoxifen.

METHODS:

Ten breast cancer patients who were treated with tamoxifen in combination with a potent CYP2D6-inhibiting antidepressant (paroxetine or fluoxetine) for at least 4 weeks were enrolled. Under close supervision by a psychiatrist, patients were switched to treatment with escitalopram or venlafaxine (weak CYP2D6-inhibiting antidepressants). Before and after the switch, pharmacokinetic blood sampling was performed over 24 h. Pharmacokinetic parameters were estimated using noncompartmental analysis. Adverse effects were recorded during the study.

RESULTS:

Endoxifen exposure was ~3-fold higher during escitalopram co-administration than during paroxetine or fluoxetine co-administration (median 387 nM·h [range 159-637 nM·h] versus 99.2 nM·h [range 70.0-210 nM·h]; P = 0.012; Wilcoxon signed-rank test). The ratio of endoxifen to N-desmethyltamoxifen and the ratio of 4-hydroxytamoxifen to tamoxifen increased by 3.3- and ~1.5-fold, reflecting increased CYP2D6 activity. Antidepressant switching did not result in psychiatric problems or antidepressant-related adverse effects.

CONCLUSION:

In this study, switching to the weak CYP2D6 inhibitor escitalopram was safe and feasible and resulted in clinically relevant rises in endoxifen concentrations. We therefore advise switching paroxetine and fluoxetine to escitalopram in patients using tamoxifen. However, switching should always be weighed in individual patients.

PMID:
26446141
PMCID:
PMC4756062
DOI:
10.1007/s40262-015-0315-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center